RxDoctor Payments Data

Celia Elias, MD

Family Medicine · Tucson, AZNPI 1932192747

Payments from drug & device makers

$7,590in general payments, 2019–2025

Across 444 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$860
  • GSK$810
  • Pfizer$601
  • Lilly USA, LLC$459
  • Abbott$390
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$7,558100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,590 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$168,114
Medicare patients
155
Services billed
3,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol97$133,949
TrulicityDulaglutide75$109,118
OzempicSemaglutide73$87,305
MounjaroTirzepatide57$77,821
EliquisApixaban74$77,289
ZenpepLipase/Protease/Amylase29$68,176
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$52,094
CreonLipase/Protease/Amylase11$51,489
JardianceEmpagliflozin37$48,615
Nurtec OdtRimegepant Sulfate18$38,695
LinzessLinaclotide38$35,206
MyrbetriqMirabegron50$28,971
ProliaDenosumab14$24,688
JanuviaSitagliptin Phosphate17$23,743
KerendiaFinerenone20$23,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$459$186,939132 claims
AstraZenecaFarxiga$860$133,94997 claims
PfizerEliquis, Nurtec Odt$601$115,98392 claims
AbbVieCreon, Linzess, Restasis$1,128$93,96660 claims
Novo NordiskOzempic$289$87,30573 claims
Aimmune Therapeutics, Inc.Zenpep$74$68,17629 claims
GSKTrelegy Ellipta, Breo Ellipta$810$59,34374 claims
Boehringer IngelheimJardiance$272$48,61537 claims
Astellas Pharma US IncMyrbetriq$145$28,97150 claims
AmgenProlia$216$24,68814 claims
MerckJanuvia$179$23,74317 claims
BayerKerendia$243$23,24720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →